Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
New Jersey, United States, - The latest research report added to Intellect Repository of market research is an in-depth analysis of the worldwide Mandarin...